Compare Stocks

→ The Gold Grab of the Century (From Colonial Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ONCY Oncolytics Biotech	$1.17	$1.07	$0.88 ▼ $3.39	$88.24M	1.91	227,614 shs	98,155 shs
OPNT Opiant Pharmaceuticals		$20.58	$7.34 ▼ $29.25	$108.83M	0.84	77,920 shs	562,700 shs
PRAX Praxis Precision Medicines	$54.54 +0.7%	$53.40	$12.45 ▼ $67.21	$933.18M	2.87	217,177 shs	169,370 shs
VHAQ Viveon Health Acquisition	$10.00	$8.34	$0.00 ▼ $12.48	$66.50M	-0.12	27 shs	2,453 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ONCY Oncolytics Biotech	-0.85%	+6.42%	+5.45%	+0.87%	-28.40%
OPNT Opiant Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PRAX Praxis Precision Medicines	+0.70%	-0.47%	+2.91%	+30.57%	+249.62%
VHAQ Viveon Health Acquisition	0.00%	0.00%	+11.11%	-11.97%	-9.09%

The Gold Grab of the Century (Ad)

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ONCY Oncolytics Biotech	1.2716 of 5 stars	3.5	4.0	0.0	0.0	1.2	0.0	0.0
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	1.888 of 5 stars	3.4	3.0	0.0	0.0	2.6	1.7	0.0
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ONCY Oncolytics Biotech	3.00	Buy	$4.00	241.88% Upside
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	2.80	Moderate Buy	$105.80	93.99% Upside
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest OPNT, ONCY, PRAX, and VHAQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/1/2024	PRAX Praxis Precision Medicines	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$117.00
4/26/2024	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
4/4/2024	ONCY Oncolytics Biotech	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$3.00
3/26/2024	PRAX Praxis Precision Medicines	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $128.00
3/26/2024	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
3/6/2024	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
2/14/2024	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A
OPNT Opiant Pharmaceuticals	$47.78M	0.00	N/A	24.75	$9.92 per share	0.00
PRAX Praxis Precision Medicines	$2.45M	380.89	N/A	N/A	$7.92 per share	6.89
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	($3.22) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ONCY Oncolytics Biotech	-$20.56M	-$0.30	N/A	N/A	N/A	N/A	-105.97%	-72.80%	5/9/2024 (Confirmed)
OPNT Opiant Pharmaceuticals	$3.01M	-$6.56	N/A	N/A	N/A	-147.90%	-97.03%	-59.66%	N/A
PRAX Praxis Precision Medicines	-$123.28M	-$23.66	N/A	N/A	N/A	-5,037.88%	-151.02%	-115.60%	5/9/2024 (Estimated)
VHAQ Viveon Health Acquisition	-$610K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest OPNT, ONCY, PRAX, and VHAQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2024	N/A	ONCY Oncolytics Biotech	-$0.09	N/A	+$0.09	N/A	N/A	N/A
3/7/2024	Q4 2023	ONCY Oncolytics Biotech	-$0.11	-$0.04	+$0.07	-$0.04	N/A	N/A
3/5/2024	12/31/2023	PRAX Praxis Precision Medicines	-$3.05	-$2.97	+$0.08	-$2.97	$0.30 million	$0.52 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ONCY Oncolytics Biotech	N/A	9.01	9.01
OPNT Opiant Pharmaceuticals	0.60	5.48	5.48
PRAX Praxis Precision Medicines	N/A	5.39	5.39
VHAQ Viveon Health Acquisition	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ONCY Oncolytics Biotech	6.82%
OPNT Opiant Pharmaceuticals	42.39%
PRAX Praxis Precision Medicines	67.84%
VHAQ Viveon Health Acquisition	22.14%

Insider Ownership

Company	Insider Ownership
ONCY Oncolytics Biotech	0.10%
OPNT Opiant Pharmaceuticals	25.15%
PRAX Praxis Precision Medicines	2.70%
VHAQ Viveon Health Acquisition	75.27%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ONCY Oncolytics Biotech	29	75.42 million	75.35 million	Not Optionable
OPNT Opiant Pharmaceuticals	37	5.27 million	3.87 million	Not Optionable
PRAX Praxis Precision Medicines	82	17.11 million	16.65 million	Optionable
VHAQ Viveon Health Acquisition	N/A	6.65 million	1.64 million	Not Optionable

OPNT, ONCY, PRAX, and VHAQ Headlines

Source	Headline
	Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - Updated finance.yahoo.com - May 3 at 10:28 AM
	Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success finance.yahoo.com - May 2 at 3:36 PM
	Viveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination Process finanznachrichten.de - February 28 at 3:42 PM
	VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS globenewswire.com - February 27 at 4:45 PM
	NYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ) finance.yahoo.com - February 21 at 7:40 PM
	Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE finance.yahoo.com - December 27 at 7:32 PM
	NYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ) tmcnet.com - December 22 at 6:29 PM
	San Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas. finance.yahoo.com - November 13 at 8:17 PM
	NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS) finance.yahoo.com - October 24 at 12:34 PM
	VHAQ-R Viveon Health Acquisition Corp. seekingalpha.com - September 23 at 7:56 AM
	Viveon Health Acquisition Received Audit Opinion With Going Concern Explanation marketwatch.com - September 15 at 6:11 PM
	VIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATION finance.yahoo.com - September 15 at 6:11 PM
	Viveon Healthcare Increases Consideration Offered to Clearday Shareholders finance.yahoo.com - September 5 at 6:45 PM
	SPAC Viveon ups merger consideration for Clearday to $500M msn.com - August 29 at 4:18 PM
	Viveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreement finance.yahoo.com - August 29 at 4:18 PM
	VIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILING finance.yahoo.com - April 25 at 9:05 PM
	Viveon Health Acquisition Corp. (VHAQ-RT) finance.yahoo.com - April 18 at 3:32 PM
	(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to Market finance.yahoo.com - April 12 at 12:15 PM
	SPAC Viveon to merge with senior-care tech provider Clearday seekingalpha.com - April 6 at 1:59 PM
	SPAC Viveon signs merger LOI with health monitoring platform Clearday msn.com - March 1 at 2:48 PM
	Viveon Health Acquisition Corp. and Clearday Inc. Announce Signed Letter of Intent to Merge and Create a Leading Longevity Care Company finance.yahoo.com - March 1 at 9:48 AM
	SPAC Viveon terminates planned merger with Suneva Medical msn.com - February 6 at 6:48 PM
	Viveon Health Acquisition Corp. Announces Termination of Merger Agreement with Suneva Medical, Inc. finance.yahoo.com - February 3 at 12:53 PM
	VIVEON HEALTH ACQUISITION CORP. Announces Adjournment of Special Meeting in Connection with ... kentuckytoday.com - January 27 at 10:07 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Oncolytics Biotech

NASDAQ:ONCY

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Opiant Pharmaceuticals

NASDAQ:OPNT

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Praxis Precision Medicines

NASDAQ:PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Viveon Health Acquisition

NYSE:VHAQ

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial